At a glance
| Product | Imcivree |
|---|---|
| Target | MC4 receptor |
| Route | Subcutaneous injection |
| Acquired HO age | 4 years and older |
| Selected genetic/syndromic age | 2 years and older |
Overview
Imcivree is used when a defined disruption of hypothalamic appetite signaling makes MC4 receptor activation an appropriate therapeutic target. The 2026 U.S. label includes acquired hypothalamic obesity from age four, and Bardet-Biedl syndrome or qualifying POMC, PCSK1 or LEPR deficiency from age two. Genetic findings require appropriate interpretation; a benign variant or a commercial genetic result alone is not sufficient. Diagnosis and clinical context distinguish this treatment from broader obesity medicines. Its evidence should therefore be understood in relation to the specific disorder rather than body weight alone.
How it works
Setmelanotide activates melanocortin-4 receptors in brain pathways regulating hunger, satiety and energy expenditure. It can restore downstream signaling when certain upstream pathways are impaired. Activity at melanocortin-1 receptors explains increased skin pigmentation. This targeted biology is why the medicine can help selected rare disorders while the label does not expect the same effectiveness in unrelated genetic syndromes or general polygenic obesity.
Current indication boundaries
Acquired hypothalamic obesity, Bardet-Biedl syndrome and qualifying POMC, PCSK1 or LEPR deficiency are separate labeled groups. The label excludes general polygenic obesity and deficiencies based on variants classified as benign or likely benign.
Supporting sources [1]
Rare-disease trial evidence
Trials in POMC and LEPR deficiency measured body-weight reduction and hunger in small, genetically defined groups. The results support targeted treatment, but small rare-disease cohorts cannot be treated as evidence for the much larger population with common obesity.
Supporting sources [2]
Pigmentation, mood and sexual effects
Generalized darkening of skin, changes in moles and new pigmented lesions require attention. Depression or suicidal thoughts, spontaneous erections and other sexual adverse reactions have occurred. Serious hypersensitivity is possible.
Supporting sources [1]
Additional considerations in acquired hypothalamic obesity
The current label adds attention to acute adrenal insufficiency and sodium disturbances in patients with acquired hypothalamic obesity, especially those with central diabetes insipidus. These problems reflect the broader endocrine consequences of hypothalamic disease.
Supporting sources [1]
What the diagnosis contributes
A specialist assessment connects the clinical syndrome, genetic or structural findings, hunger pattern and other pituitary deficits. The decision is not based on a weight threshold alone, and skin examination and mental-health follow-up remain part of the treatment context.
Supporting sources [1]
Reading this profile
Jurisdiction: United States — FDA-approved prescription medicine; indication and formulation restrictions apply.. Molecular class: Melanocortin-4 receptor agonist cyclic peptide.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- FDA: Imcivree prescribing information, 2026 ↗Regulatory source · Checked 2026-10-27
- Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. ↗Original research · Checked 2026-10-27